Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations

Annals of Thoracic Surgery

Volumn 101, Issue 2, 2016, Pages 473-480

  Kim, Tae Jung ^a   Lee, Choon Taek ^a   Jheon, Sang Hoon ^a   Park, Jeong Soo ^b   Chung, Jin Haeng ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Dankook University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CONTRAST MEDIUM; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROTEIN TYROSINE KINASE;

ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; COLLIMATOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PET-CT SCANNER; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WILD TYPE; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MUTATION; RADIOGRAPHY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84974784686     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2015.07.062     Document Type: Article

References (30)

1. 1 Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
2. 2 Lynch, T.J., Bell, D.W., Sordella, R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004), 2129–2139.
3. 3 Paez, J.G., Jänne, P.A., Lee, J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
4. 4 Kwak, E.L., Bang, Y.-J., Camidge, D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363 (2010), 1693–1703.
5. 5 Koivunen, J.P., Mermel, C., Zejnullahu, K., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14 (2008), 4275–4283.
6. 6 Soda, M., Choi, Y.L., Enomoto, M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561–566.
7. 7 Wong, D.W., Leung, E.L., So, K.K., et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115 (2009), 1723–1733.
8. 8 Jeong, C.J., Lee, H.Y., Han, J., et al. Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma. Clin Nucl Med 40 (2015), e34–e39.
9. 9 Yamamoto, S., Korn, R.L., Oklu, R., et al. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 272 (2014), 568–576.
10. 10 Choi, C.M., Kim, M.Y., Hwang, H.J., Lee, J.B., Kim, W.S., Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation. Radiology 275 (2015), 272–279.
11. 11 Fukui, T., Yatabe, Y., Kobayashi, Y., et al. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 77 (2012), 319–325.
12. 12 Beasley, M.B., Brambilla, E., Travis, W.D., The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 40 (2005), 90–97.
13. 13 Martelli, M.P., Sozzi, G., Hernandez, L., et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174 (2009), 661–670.
14. 14 Shaw, A.T., Yeap, B.Y., Mino-Kenudson, M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27 (2009), 4247–4253.
15. 15 Kozuki, T., Hisamoto, A., Tabata, M., et al. Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. Lung Cancer 58 (2007), 30–35.
16. 16 Rusch, V.W., Crowley, J., Giroux, D.J., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2 (2007), 603–612.
17. 17 Kim, T.J., Goo, J.M., Lee, K.W., Park, C.M., Lee, H.J., Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule. Lung Cancer 64 (2009), 171–178.
18. 18 Hanley, J.A., McNeil, B.J., The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982), 29–36.
19. 19 Miller, V.A., Kris, M.G., Shah, N., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 (2004), 1103–1109.
20. 20 Haneda, H., Sasaki, H., Shimizu, S., et al. Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. Lung Cancer 52 (2006), 47–52.
21. 21 Blons, H., Côté, J.-F., Le Corre, D., et al. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol 30 (2006), 1309–1315.
22. 22 Lee, H.J., Kim, Y.T., Kang, C.H., et al. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology 268 (2013), 254–264.
23. 23 Lee, H.Y., Choi, Y.-L., Lee, K.S., et al. Pure ground-glass opacity neoplastic lung nodules: histopathology, imaging, and management. AJR Am J Roentgenol 202 (2014), W224–W233.
24. 24 Travis, W.D., Brambilla, E., Noguchi, M., et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6 (2011), 244–285.
25. 25 Rodig, S.J., Mino-Kenudson, M., Dacic, S., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15 (2009), 5216–5223.
26. 26 Yoshida, A., Tsuta, K., Nakamura, H., et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35 (2011), 1226–1234.
27. 27 Blackhall, F.H., Peters, S., Bubendorf, L., et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol 32 (2014), 2780–2787.
28. 28 Lee, J.K., Park, H.S., Kim, D.W., et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer 118 (2012), 3579–3586.
29. 29 Wu, S.G., Kuo, Y.W., Chang, Y.L., et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 7 (2012), 98–104.
30. 30 Yang, P., Kulig, K., Boland, J.M., et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 7 (2012), 90–97.